FDA warns of liver injury risk from tolvaptan

01/28/2013 | Medscape (free registration)

Otsuka America Pharmaceutical's kidney drug Samsca, or tolvaptan, may cause irreversible and potentially deadly liver injury, and providers should promptly conduct liver tests on patients reporting symptoms, according to the FDA. Otsuka informed the FDA that three trial participants who took tolvaptan developed liver problems, and their conditions improved after they stopped taking the drug.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC